Patents by Inventor Roland Kellner

Roland Kellner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210008160
    Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).
    Type: Application
    Filed: June 4, 2018
    Publication date: January 14, 2021
    Applicants: Merck Patent GmbH, ABLYNX NV
    Inventors: Soren STEFFENSEN, Gerald BESTE, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL, Sven LINDEMANN, Roland KELLNER, Ralf GUENTHER
  • Publication number: 20200317802
    Abstract: The present invention relates to immunoglobulins that bind ADAMTSS and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein.
    Type: Application
    Filed: June 4, 2018
    Publication date: October 8, 2020
    Applicants: Merck Patent GmbH, ABLYNX NV
    Inventors: Marie-Ange BUYSE, Guy HERMANS, Sven LINDEMANN, Hans GUEHRING, Ralf GUENTHER, Roland KELLNER
  • Publication number: 20160279213
    Abstract: The invention relates to a therapeutically effective truncated survivin and its therapeutic use as vaccine in a liposomal preparation, wherein the survivin fragment is preferably gluconoylated, and said liposomal preparation elicits in-vivo anti-tumor activity. The invention is directed, in more detail, to a cancer vaccine comprising a fragment of human survivin that is specifically effective in conjunction with an lipid adjuvant. The invention relates in more detail to a liposomal vaccine delivery system comprising an active truncated survivin molecule as tumor antigen and a chiral cationic lipid, for example R-DOTAP acting as adjuvant, which is part of the liposome preparation, wherein the liposomal drug delivery system is optimized with regard to its lipid and adjuvant components, physical or physicochemical parameters, and the final therapeutic efficacy of the released truncated survivin molecules.
    Type: Application
    Filed: December 16, 2014
    Publication date: September 29, 2016
    Inventors: Simon Geissler, Patrizia Boniforte, Joerg Plaschke, Markus Weigandt, Stefan Jaekel, Roland Kellner, Thomas Rysiok, Dirk Mueller-Pompalla, Kenneth Hance
  • Patent number: 9151743
    Abstract: The invention relates to a method for screening compounds, which inhibit MetAP2 activity, by providing a cellular system or a sample thereof being capable of expressing MetAP2 and/or EEF1A, incubating at least a portion of the system with compounds to be screened, and detecting MetAP2 inhibition by determining EEF1A with N-terminal methionine residue (MetEEF1A). Another object of the invention concerns a method for monitoring physiological and/or pathological conditions, which are caused, mediated and/or propagated by MetAP2 activity, by administering an effective amount of at least a single compound to a mammal in need of such treatment and determining MetEEF1A in a biological sample withdrawn from the mammal. The invention also relates to the use of EEF1A as biomarker.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: October 6, 2015
    Assignee: MERCK PATENT GMBH
    Inventors: Roland Kellner, Frank Zenke, Joerg Bomke
  • Publication number: 20110275088
    Abstract: The invention relates to a method for screening compounds, which inhibit MetAP2 activity, by providing a cellular system or a sample thereof being capable of expressing MetAP2 and/or EEF1A, incubating at least a portion of the system with compounds to be screened, and detecting MetAP2 inhibition by determining EEF1A with N-terminal methionine residue (MetEEF1A). Another object of the invention concerns a method for monitoring physiological and/or pathological conditions, which are caused, mediated and/or propagated by MetAP2 activity, by administering an effective amount of at least a single compound to a mammal in need of such treatment and determining MetEEF1A in a biological sample withdrawn from the mammal. The invention also relates to the use of EEF1A as biomarker.
    Type: Application
    Filed: October 5, 2009
    Publication date: November 10, 2011
    Inventors: Roland Kellner, Frank Zenke, Joerg Bomke
  • Patent number: 7432348
    Abstract: 180 KDa protein histidine phosphatase interacting protein (PHPIP-180) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-180 polypeptides and polynucleotides in diagnostic assays.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: October 7, 2008
    Assignee: Merck Patent GmbH
    Inventors: Roland Kellner, Bjoern Hock
  • Patent number: 7348160
    Abstract: The present invention relates to the use of compounds and to methods for the qualitative and/or quantitative determination of the activity of phosphoamidases or protein phosphoamidases specific for hydrolyzing phosphoamide (P—N) bonds N-phosphorylated basic amino acids like phospholysine, phosphoarginine and phosphohistidine.
    Type: Grant
    Filed: October 10, 2003
    Date of Patent: March 25, 2008
    Assignee: Merck Patent GmbH
    Inventors: Roland Kellner, Ansgar Wegener
  • Patent number: 7193051
    Abstract: PHPIP-240 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-240 polypeptides and polynucleotides in diagnostic assays.
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: March 20, 2007
    Assignee: Merck Patent GmbH
    Inventors: Bjoern Hock, Klaus Duecker, Roland Kellner
  • Patent number: 7176285
    Abstract: PHPIP-120 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed, also disclosed are methods for utilizing PHPIP-120 polypeptides and polynucleotides in diagnostic assays.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: February 13, 2007
    Assignee: Merck Patent GmbH
    Inventors: Bjoern Hock, Klaus Duecker, Roland Kellner
  • Publication number: 20060153825
    Abstract: The invention relates to the use of polypeptides with protein histidine phosphatase activity derived from mammalians, antibodies directed against them and DNA or RNA sequences complementary to mRNA sequences encoding polypeptides with protein histidine phosphatase activity for the modulation of ATP-citrate lyase and treatment of correlated pathophysiologic functions.
    Type: Application
    Filed: March 4, 2002
    Publication date: July 13, 2006
    Applicant: Merck Patent GmbH
    Inventors: Roland Kellner, Susanne Klumpp
  • Publication number: 20050124023
    Abstract: The present invention relates to the use of compounds and to methods for the qualitative and/or quantitative determination of the activity of phosphoamidases or protein phosphoamidases specific for hydrolyzing phosphoamide (P—N) bonds. N-phosphorylated basic amino acids like phospholysine, phosphoarginine and phosphohistidine.
    Type: Application
    Filed: October 10, 2003
    Publication date: June 9, 2005
    Inventors: Roland Kellner, Ansgar Wegener
  • Publication number: 20050070002
    Abstract: PHPIP-120 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed, also disclosed are methods for utilizing PHPIP-120 polypeptides and polynucleotides in diagnostic assays.
    Type: Application
    Filed: January 25, 2002
    Publication date: March 31, 2005
    Applicant: Merck Patent GmbH
    Inventors: Bjorn Hock, Klaus Ducker, Roland Kellner
  • Publication number: 20040265818
    Abstract: PHPIP-180 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-180 polypeptides and polynucleotides in diagnostic assays.
    Type: Application
    Filed: January 13, 2004
    Publication date: December 30, 2004
    Inventors: Roland Kellner, Bjoern Hock
  • Patent number: 6812015
    Abstract: The invention relates to a novel enzyme, histidine protein phosphatase, which is derived from mammalian sources, and its homologue variants. The invention further relates to DNA sequences encoding said proteins, to a process for preparing the latter, and to antibodies directed against them. The novel phosphatase can be used for diagnosis of pathological states of cell regulation and cell growth and as pharmaceutical drug which can be administered in conjunction with pathological disorders related to malfunctions of said enzyme.
    Type: Grant
    Filed: September 4, 2001
    Date of Patent: November 2, 2004
    Assignee: Merck Patent Gesellschaft
    Inventors: Susanne Klumpp, Roland Kellner
  • Publication number: 20040143102
    Abstract: PHPIP-240 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-240 polypeptides and polynucleotides in diagnostic assays.
    Type: Application
    Filed: August 14, 2003
    Publication date: July 22, 2004
    Inventors: Bj?ouml;rn Hock, Klaus Dcker, Roland Kellner
  • Publication number: 20040096916
    Abstract: The present invention relates to tumor markers that can be used for creening, for diagnosis, prognosis and dentification of subtpyes of renal cell carcinoma. The present invention also relates to the use of the identified antigenic proteins in immunoassays and to the use of the tumor markers as immunogens for stimulation of an immune response. The invention further relates to the use ofhte tumor markers for the manufacture of antibodies and antibody fusion proteins directed to the tumor markers.
    Type: Application
    Filed: October 1, 2003
    Publication date: May 20, 2004
    Inventors: Roland Kellner, Kerstin Matzku, Barbara Seliger, Rudolf Lichtenfels
  • Patent number: 5843709
    Abstract: A bacterial host is described which is transformed by a plasmid coding for a polypeptide precursor wherein the host comprises a multi-enzyme complex capable of reacting with the expressed polypeptide precursor to produce a polypeptide comprising at least one dehydroamino acid and/or at least one lanthione bridge. A process for producing a polypeptide comprising at least one dehydroamino acid and/or at least one lanthione bridge, such as gallidermin, is also described. A plasmid capable of transforming a bacterial host is additionally described.Also disclosed are recombinant DNA molecules which specify Epi B, Epi C, Epi D, Epi P and Epi Q, enzymes which are involved in the biosynthesis of lantibiotic epidermin.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 1, 1998
    Assignee: Dr. Karl Thomae GmbH
    Inventors: Karl-Dieter Entian, Friedrich Gotz, Norbert Schnell, Johannes Augustin, Germar Engelke, Ralf Rosenstein, Cortina Kaletta, Cora Klein, Bernd Wieland, Thomas Kupke, Gunther Jung, Roland Kellner
  • Patent number: 5837485
    Abstract: A bacterial host is described which is transformed by a plasmid coding for a polypeptide precursor wherein the host comprises a multi-enzyme complex capable of reacting with the expressed polypeptide precursor to produce a polypeptide comprising at least one dehydroamino acid and/or at least one lanthionine bridge. A process for producing a polypeptide comprising at least one dehydroamino acid and/or at least one lanthionine bridge, such as gallidermin, is also described. A plasmid capable of transforming a bacterial host is additionally described.Also disclosed are recombinant DNA molecules which specify Epi B, Epi C, Epi D, Epi P and Epi Q, enzymes which are involved in the biosynthesis of lantibiotic epidermin.
    Type: Grant
    Filed: February 22, 1995
    Date of Patent: November 17, 1998
    Assignee: Dr. Karl Tomae GmbH
    Inventors: Karl-Dieter Entian, Friedrich Gotz, Norbert Schnell, Johannes Augustin, Germar Engelke, Ralf Rosenstein, Cortina Kaletta, Cora Klein, Bernd Wieland, Thomas Kupke, Gunther Jung, Roland Kellner
  • Patent number: 5231013
    Abstract: A new polycyclic peptide antibiotic termed gallidermin is disclosed and described, together with a process for producing such antibiotic by fermination of a new microorganism, Staphylococcus gallinarum (DSM 4616).
    Type: Grant
    Filed: May 18, 1989
    Date of Patent: July 27, 1993
    Inventors: Gunther Jung, Roland Kellner, Hans Zahner, Friedrich Gotz, Thomas Horner, Rolf G. Werner, Hermann Allgaier